AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03224351
Drug: IVA
RxNorm normalized name: Viva
DrugBank: Adenosine (DB00640)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT00956436
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard dosing of Sorafenib
Trial: NCT03979066
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
Trial: NCT01299558
Drug: fluticasone furoate//GW642444
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
Trial: NCT01299558
Drug: fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single IV dose of FF (250mcg)
Trial: NCT03224351
Drug: TEZ
RxNorm normalized name: Otezla
DrugBank: Apremilast (DB05676)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet for oral administration.
Trial: NCT03224351
Drug: VX-561
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral administration.
Trial: NCT03224351
Drug: Placebo (matched to VX-659/TEZ/VX-561)
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-659, TEZ and VX-561.
Trial: NCT03389893
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
Trial: NCT00003424
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02301715
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
Trial: NCT01146808
Drug: Adefovir dipivoxil and hepatitis B vaccination
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
Trial: NCT00455286
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00455286
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01968161
Drug: Asenapine
RxNorm normalized name: Asenapine
DrugBank: Asenapine (DB06216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02448719
Drug: TAK-792 30 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 30 mg was administered in the morning after a fast.
Trial: NCT02448719
Drug: TAK-792 100 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 100 mg was administered in the morning after a fast.
Trial: NCT02448719
Drug: TAK-792 250 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 250 mg was administered in the morning after a fast.
Trial: NCT02448719
Drug: TAK-792 500 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 500 mg was administered in the morning after a fast or after breakfast.
Trial: NCT04323631
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02448719
Drug: TAK-792 750 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 750 mg was administered in the morning after a fast.
Trial: NCT03566225
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin sensitizing agents
Trial: NCT02448719
Drug: TAK-792 1250 mg
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-792 1250 mg was administered in the morning after a fast.
Trial: NCT01232556
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
Trial: NCT01232556
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
Trial: NCT03706313
Drug: 15mL 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
Trial: NCT03706313
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
Trial: NCT01232556
Drug: rituximab + gemcitabine
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
Trial: NCT01232556
Drug: rituximab +bendamustine
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
Trial: NCT01548079
Drug: Ursodeoxycholic Acid (UDCA)
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg/day UDCA in three weeks
Trial: NCT00055601
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
Trial: NCT00055601
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
Trial: NCT00055601
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
Trial: NCT03566225
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin sensitizing agent
Trial: NCT03566225
Drug: Clomiphene Citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction drug
Trial: NCT00236002
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 70mgm once a week for one year
Trial: NCT00136539
Drug: Herceptin
RxNorm normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously once weekly for 12 weeks prior to surgery.
Trial: NCT00136539
Drug: Taxol
RxNorm normalized name: Taxol
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
Trial: NCT00136539
Drug: Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given every three weeks for 12 weeks after surgery.
Trial: NCT00136539
Drug: Cytoxan
RxNorm normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given every three weeks for 12 weeks after surgery.
Trial: NCT01149356
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01149356
Drug: Goserelin Acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given subcutaneously to premenopausal patients
Trial: NCT01075048
Drug: Tivantinib
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Trial: NCT00110110
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given at 28 mg/kg/dose.
Trial: NCT00110110
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given at 33 mg/kg/dose
Trial: NCT00110110
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given at 12 mg/kg/dose
Trial: NCT00110110
Drug: vincristine sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
Trial: NCT02824666
Drug: ATI-9242
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg
Trial: NCT01075048
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Trial: NCT01075048
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Trial: NCT01788020
Drug: Dexamethasone, Rituximab, Cyclophosphamide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01788020
Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00759915
Drug: morphine sulfate extended-release capsules
RxNorm normalized name: Morphine Sulfate Extended-Release Capsules
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 10 mg, single-dose capsule
Trial: NCT00759915
Drug: KADIAN (morphine sulfate extended-release) capsules
RxNorm normalized name: morphine sulfate Extended Release Oral Capsule [Kadian]
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 20 mg, single-dose capsule
Trial: NCT04698642
Drug: CBL-514
RxNorm normalized name: OH-Cbl
DrugBank: Hydroxocobalamin (DB00200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both sides of the abdominal region will receive CBL-514.
Trial: NCT03818685
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Radiotherapy will be maintained in each Arm.
Trial: NCT03818685
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Radiotherapy will be maintained in each Arm.
Trial: NCT01662726
Drug: Irosustat
RxNorm normalized name: Irosustat
DrugBank: Irosustat (DB02292)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
Trial: NCT01481220
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
Trial: NCT00001267
Drug: zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02134977
Drug: Leuprorelin Acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin Acetate SR 11.25 mg Injection Kit
Trial: NCT00313690
Drug: Bortezomib, Docetaxel and Cisplatin
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04360317
Drug: Combination of SH003 and Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination of SH003 and Docetaxel
Trial: NCT01328015
Drug: Oxybutynin 5 mg pills
RxNorm normalized name: oxyBUTYnin Pill
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks.
Trial: NCT03809429
Drug: FE 999049 + GnRH agonist (GONAPEPTYL)
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-filled injection pen
Trial: NCT03809429
Drug: FE 999049 + GnRH antagonist (CETROTIDE)
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder and solvent for solution for injection
Trial: NCT02323282
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04103060
Drug: Cerdulatinib 0.37% gel
DrugBank: Cerdulatinib (DB15499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
Trial: NCT02273817
Drug: Ciclesonide nasal spray, 50 μg per actuation.
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~1. Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~2. Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~3. Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days.
Trial: NCT04172987
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01530269
Drug: C11-Sodium Acetate
RxNorm normalized name: Choline C11
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PET Imaging with C11-Sodium Acetate
Trial: NCT01009593
Drug: ABT-869
RxNorm normalized name: ABT-925
DrugBank: ABT-639 (DB15055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
Trial: NCT01009593
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
Trial: NCT00712855
Drug: sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg orally, twice a day continuously in each cycle
Trial: NCT00892931
Drug: Azixa
DrugBank: Verubulin (DB05585)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
Trial: NCT00737971
Drug: Bevacizumab intravitreal
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
Trial: NCT00737971
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
Trial: NCT00737971
Drug: Triamcinolone + Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
Trial: NCT04390022
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of STROMECTOL® tablets at 400mcg/kg
Trial: NCT00852540
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
Trial: NCT02619149
Drug: Piperacillin-tazobactam combination product
RxNorm normalized name: piperacillin / tazobactam
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
Trial: NCT02619149
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline iv as placebo control
Trial: NCT00735709
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Encapsulated immediate-release vortioxetine tablets
Trial: NCT01925170
Drug: Technetium (99mTc) sestamibi
RxNorm normalized name: technetium (99mTc) sestamibi
DrugBank: Technetium Tc-99m sestamibi (DB09161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
Trial: NCT02510937
Drug: CC-90001
RxNorm normalized name: CC-90001
DrugBank: CC-90001 (DB18445)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00789321
Drug: Comparator: amlodipine besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 5 mg tablets amlodipine daily for 6 weeks.
Trial: NCT02280434
Drug: CBP-307
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00801944
Drug: Solifenacin succinate
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02068209
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
Trial: NCT02391272
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no